Longer Term Growth of Diabetic Neuropathy Market Will Be Driven by Launches of Disease-Modifying Therapies, According to a New Report from Decision
WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2016 Genentech/Roche's Lucentis and Eli Lilly's ruboxistaurin will drive the markets for the treatment of diabetic retinopathy and diabetic nephropathy.
The new Pharmacor report entitled Diabetic Complications: Retinopathy, Neuropathy, and Nephropathy finds that, over the next decade, treatment of diabetic complications will expand considerably beyond tight control of blood pressure and glucose levels. Lucentis and ruboxistaurin will come the closest to achieving blockbuster status as treatments for diabetic complications in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additionally, although promising drug classes with potential disease-modifying activity that include PKC inhibitors and aldose reductase inhibitors have suffered a decade of setbacks and disappointing efficacy data, the report finds that longer-term market growth will be driven by several of these novel therapies.
Therapies for the painful symptoms of diabetic neuropathy will continue to dominate sales, and few patients suffering non-painful diabetic neuropathy will receive treatment until the launches of disease-modifying therapies near the midpoint of the 2006-2016 forecast period.
"The diabetic neuropathy market will experience growth during the
second half of our study period because of increasing use of Pfizer's
antiepileptic drug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which
are both approved specifically for the treatment of diabetic neuropathic
pain," said Donny Wong, Ph.D., analyst at Decision Resources. "Longer term
|SOURCE Decision Resources|
Copyright©2007 PR Newswire.
All rights reserved